ViroPharma Incorporated
730 Stockton Drive
Exton
Pennsylvania
19341
United States
Tel: 610-458-7300
Fax: 610-458-7380
Website: http://www.viropharma.com/
Email: questions@viropharma.com
About ViroPharma Incorporated
ViroPharma Incorporated is a global biotechnology company dedicated to developing and commercializing products that help address dangerous, potentially life-threatening conditions such as hereditary angioedema (HAE), seizures in children and adolescents, and adrenal insufficiency. ViroPharma is headquartered in Exton, PA and has operations throughout Europe.ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs. ViroPharma has gained commercial approval for three important therapeutics in the United States or Europe, with several others in clinical development. For example, our product Cinryze (R) (C1 Esterase Inhibitor (human)) is indicated in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In Europe, it is indicated for prophylaxis against HAE attacks, pre-procedure prophylaxis, and acute treatment of attacks of HAE in children and adolescents with HAE.
HAE is a rare inherited disorder which is characterized by painful swelling that can appear in various parts of the body. It most commonly affects the hands, feet, face, abdomen, urogenital tract, and upper respiratory tract. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attack, life-threatening. If left untreated, HAE can result in a mortality rate as high as 40%, primarily due to upper airway obstruction or suffocation in undiagnosed patients.
ViroPharma is engaged in life-cycle management work with Cinryze on additional indications, formulations, and territories. In addition, our preclinical and clinical pipeline includes non-toxigenic C. difficile (NTCD), targeting prevention of recurrence of disease following therapy for acute C. difficile infection (CDI), a phase 1 compound targeting a rare disease called Friedreich's ataxia, several clinical and investigator initiated studies of C1 esterase inhibitor in diseases mediated by the complement cascade, and our Phase 2 agent called maribavir, targeting transplant-associated cytomegalovirus (CMV) infection.
Through the success ViroPharma’s products and our management team’s savvy business model, the company’s is well positioned financially to continue to add new products that will provide hope to physicians treating patients with unmet medical needs.
ViroPharma is an equal opportunity employer and promotes diversity throughout its organization. A strong foundation of shared values among the people of ViroPharma, brought together with a clear and common purpose, has contributed to the culture of ViroPharma. The company is seeking individuals with the skills and passion for results to join the ViroPharma team as part of the catalyst to future success. In addition to a rewarding work environment emphasizing teamwork, commitment and communication, ViroPharma provides competitive salaries, medical/dental benefits, a 401(k) plan and stock options.
Please visit ViroPharma’s Online Recruitment Center to complete a profile and apply.
284 articles about ViroPharma Incorporated
-
ViroPharma Incorporated Release: Health Canada Approves New Drug Submission for Cinryze™ (C1 Inhibitor [Human])
10/22/2012
-
ViroPharma Incorporated to Release 2012 Third Quarter Financial Results on October 25, 2012
10/18/2012
-
ViroPharma Incorporated Presents New Cinryze™ (C1 Esterase Inhibitor [Human]) Data on Site of Care and Adherence at the 2012 Academy of Managed Care Pharmacy Educational Conference
10/5/2012
-
FDA Lifts Temporary Hold on ViroPharma Incorporated Treatment
9/21/2012
-
ViroPharma Incorporated to Host Analyst and Investor Seminar on September 21, 2012
9/19/2012
-
ViroPharma Incorporated to Expand, Creating 151 New Jobs
9/11/2012
-
ViroPharma Incorporated to Present at the Stifel Nicolaus 2012 Healthcare Conference
8/31/2012
-
West Chester University of Pennsylvania's Pharmaceutical Product Development Program Will Feature New Lecture Series on Rare Diseases Presented by ViroPharma Incorporated
8/13/2012
-
ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
8/9/2012
-
ViroPharma Incorporated Has FDA Nod to Expand Cinryze
8/7/2012
-
ViroPharma Incorporated Provides Update on Phase 2 Clinical Evaluation of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
8/2/2012
-
ViroPharma Incorporated's Cinryze® (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up to 2.6 Years of Effectiveness in Majority of Subjects With Hereditary Angioedema
7/27/2012
-
ViroPharma Incorporated to Release 2012 Second Quarter Financial Results on August 9, 2012
7/25/2012
-
ViroPharma Incorporated Announces Initiation of Clinical Studies to Evaluate Maribavir for Treatment of Cytomegalovirus (CMV) Infection
6/4/2012
-
ViroPharma IncorporatedTo Participate In Two June Healthcare Investor Conferences
5/23/2012
-
ViroPharma Incorporated to Participate in Two May Healthcare Investor Conferences
5/3/2012
-
ViroPharma Incorporated Reports First Quarter 2012 Financial Results
5/1/2012
-
ViroPharma Incorporated Loses Bid for Order Blocking Generic Vancocin
4/25/2012
-
ViroPharma Incorporated to Release 2012 First Quarter Financial Results on May 1, 2012
4/24/2012
-
ViroPharma Incorporated Sues FDA Over Rejected Petition
4/16/2012